Puma Biotechnology
PBYI
121 hedge funds and large institutions have $113M invested in Puma Biotechnology in 2025 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 42 increasing their positions, 32 reducing their positions, and 16 closing their positions.
8,150% more call options, than puts
Call options by funds: $330K | Put options by funds: $4K
38% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 16
31% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 32
25% more capital invested
Capital invested by funds: $90M → $113M (+$22.5M)
4.81% more ownership
Funds ownership: 61.31% → 66.11% (+4.8%)
4% more funds holding
Funds holding: 116 → 121 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$2.38M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$1.62M |
| 3 |
LSV Asset Management
Chicago,
Illinois
|
+$1.54M |
| 4 |
OSAM
O'Shaughnessy Asset Management
Stamford,
Connecticut
|
+$1.05M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$834K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$3.35M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$456K |
| 3 |
Goldman Sachs
New York
|
-$294K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$294K |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$228K |
PBYI Hedge Fund Activity: Q2 2025 in Review
121 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q2 2025, worth a combined $113M — up 25% from $90M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new PBYI positions and 16 closed out — a net gain of 6 holders — while 42 added to existing stakes and 32 trimmed.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $2.38M. The largest seller was Millennium Management, cutting an estimated $3.35M.
- 121 institutional investors held Puma Biotechnology (PBYI) as of Q2 2025, up from 116 in Q1 2025.
- Funds reported $113M of Puma Biotechnology stock for Q2 2025, up 25% quarter-over-quarter.
- 22 funds opened new Puma Biotechnology positions in Q2 2025 and 16 closed out, a net change of +6 holders.
- The largest Puma Biotechnology buyer in Q2 2025 was Janus Henderson Group, an estimated $2.38M added.
- The largest Puma Biotechnology seller in Q2 2025 was Millennium Management, an estimated $3.35M sold.
Based on aggregated 13F filings for Q2 2025.